P G Nuciforo1, C Aura2, E Holmes3, L Prudkin2, J Jimenez2, P Martinez2, H Ameels4, L de la Peña5, C Ellis6, H Eidtmann7, M J Piccart-Gebhart8, M Scaltriti9, J Baselga10. 1. Molecular Oncology Laboratory, Vall D'Hebron Institute of Oncology, Barcelona, Spain pnuciforo@vhio.net. 2. Molecular Oncology Laboratory, Vall D'Hebron Institute of Oncology, Barcelona, Spain. 3. Frontier Science Scotland, Kincraig, UK. 4. BrEAST Data Centre, Jules Bordet Institute, Brussels, Belgium. 5. SOLTI Breast Cancer Research Group, Barcelona, Spain. 6. GlaxoSmithKline, Collegeville, USA. 7. University Hospital Kiel, Kiel, Germany. 8. Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium. 9. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York. 10. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York Breast Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA.
Abstract
BACKGROUND: Assessment of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) might be an important tool in identifying human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients unlikely to derive benefit from anti-HER2 therapies. However, studies to date have failed to demonstrate its predictive role in any treatment setting. PATIENTS AND METHODS: Prospectively collected baseline core biopsies from 429 early-stage HER2-positive breast cancer patients treated withtrastuzumab, lapatinib, or their combination in the Neo-ALTTO study were stained using two anti-PTEN monoclonal antibodies (CST and DAKO). The association of PTEN status and PI3K pathway activation (defined as either PTEN loss and/or PIK3CA mutation) with total pathological complete response (tpCR) at surgery, event-free survival (EFS), and overall survival (OS) was evaluated. RESULTS:PTEN loss was observed in 27% and 29% of patients (all arms, n = 361 and n = 363) for CST and DAKO, respectively. PTEN loss was more frequently observed in hormone receptor (HR)-negative (33% and 36% with CST and DAKO, respectively) compared with HR-positive tumours (20% and 22% with CST and DAKO, respectively). No significant differences in tpCR rates were observed according to PTEN status. PI3K pathway activation was found in 47% and 48% of patients (all arms, n = 302 and n = 301) for CST and DAKO, respectively. Similarly, tpCR rates were not significantly different for those with or without PI3K pathway activation. Neither PTEN status nor PI3K pathway activation were predictive of tpCR, EFS, or OS, independently of treatment arm or HR status. High inter-antibody and inter-observer agreements were found (>90%). Modification of scoring variables significantly affected the correlation between PTEN and HR status but not with tpCR. CONCLUSION: These data show that PTEN status determination is not a useful biomarker to predict resistance to trastuzumab and lapatinib-based therapies. The lack of standardization of PTEN status determination may influence correlations between expression and relevant clinical end points. CLINICAL TRIALS: This trial is registered with ClinicalTrials.gov: NCT00553358.
RCT Entities:
BACKGROUND: Assessment of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) might be an important tool in identifying humanepidermal growth factor receptor 2 (HER2)-positive breast cancerpatients unlikely to derive benefit from anti-HER2 therapies. However, studies to date have failed to demonstrate its predictive role in any treatment setting. PATIENTS AND METHODS: Prospectively collected baseline core biopsies from 429 early-stage HER2-positive breast cancerpatients treated with trastuzumab, lapatinib, or their combination in the Neo-ALTTO study were stained using two anti-PTEN monoclonal antibodies (CST and DAKO). The association of PTEN status and PI3K pathway activation (defined as either PTEN loss and/or PIK3CA mutation) with total pathological complete response (tpCR) at surgery, event-free survival (EFS), and overall survival (OS) was evaluated. RESULTS:PTEN loss was observed in 27% and 29% of patients (all arms, n = 361 and n = 363) for CST and DAKO, respectively. PTEN loss was more frequently observed in hormone receptor (HR)-negative (33% and 36% with CST and DAKO, respectively) compared with HR-positive tumours (20% and 22% with CST and DAKO, respectively). No significant differences in tpCR rates were observed according to PTEN status. PI3K pathway activation was found in 47% and 48% of patients (all arms, n = 302 and n = 301) for CST and DAKO, respectively. Similarly, tpCR rates were not significantly different for those with or without PI3K pathway activation. Neither PTEN status nor PI3K pathway activation were predictive of tpCR, EFS, or OS, independently of treatment arm or HR status. High inter-antibody and inter-observer agreements were found (>90%). Modification of scoring variables significantly affected the correlation between PTEN and HR status but not with tpCR. CONCLUSION: These data show that PTEN status determination is not a useful biomarker to predict resistance to trastuzumab and lapatinib-based therapies. The lack of standardization of PTEN status determination may influence correlations between expression and relevant clinical end points. CLINICAL TRIALS: This trial is registered with ClinicalTrials.gov: NCT00553358.
Authors: J D Jensen; A Knoop; A V Laenkholm; M Grauslund; M B Jensen; E Santoni-Rugiu; M Andersson; M Ewertz Journal: Ann Oncol Date: 2011-12-15 Impact factor: 32.976
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz Journal: Lancet Date: 2014-02-14 Impact factor: 79.321
Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Jamunarani Veeraraghavan; Carmine De Angelis; Jorge S Reis-Filho; Tomás Pascual; Aleix Prat; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff Journal: Breast Date: 2017-07-04 Impact factor: 4.380
Authors: Maki Tanioka; Cheng Fan; Joel S Parker; Katherine A Hoadley; Zhiyuan Hu; Yan Li; Terry M Hyslop; Brandelyn N Pitcher; Matthew G Soloway; Patricia A Spears; Lynn N Henry; Sara Tolaney; Chau T Dang; Ian E Krop; Lyndsay N Harris; Donald A Berry; Elaine R Mardis; Eric P Winer; Clifford A Hudis; Lisa A Carey; Charles M Perou Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Mothaffar F Rimawi; Carmine De Angelis; Alejandro Contreras; Fresia Pareja; Felipe C Geyer; Kathleen A Burke; Sabrina Herrera; Tao Wang; Ingrid A Mayer; Andres Forero; Rita Nanda; Matthew P Goetz; Jenny C Chang; Ian E Krop; Antonio C Wolff; Anne C Pavlick; Suzanne A W Fuqua; Carolina Gutierrez; Susan G Hilsenbeck; Marilyn M Li; Britta Weigelt; Jorge S Reis-Filho; C Kent Osborne; Rachel Schiff Journal: Breast Cancer Res Treat Date: 2017-11-07 Impact factor: 4.872
Authors: Kari B Wisinski; Amye J Tevaarwerk; Mark E Burkard; Murtuza Rampurwala; Jens Eickhoff; Maria C Bell; Jill M Kolesar; Christopher Flynn; Glenn Liu Journal: Clin Cancer Res Date: 2016-03-29 Impact factor: 12.531